Glaukos Corporation Glaukos Corporation

Glaukos Corporation

GKOS

Rang in Aktien #1986
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Aktienkurs
$177.09
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$10.45B
Veränderung (1 Tag)
1.76%
Veränderung (1 Jahr)
131.10%
Land
US
Handel Glaukos Corporation (GKOS)

Kategorie

Healthcare
Kursverlauf für Glaukos Corporation (GKOS)
Höchster Schlusskurs: $166.80 am 2026-10-01

Niedrigster Schlusskurs: $29.05 am 2015-06-01
Kursverlauf der Aktie von Glaukos Corporation von 2015 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 16.37%
2025 -22.38%
2024 97.91%
2023 64.84%
2022 1.09%
2021 -38.87%
2020 24.29%
2019 -5.51%
2018 133.10%
2017 -22.73%
2016 38.93%
2015 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$100.56 -21.41%
US
$93.07 -2.95%
IE
$297.13 -23.49%
US
$44.47 -57.18%
US
$46.69 -18.50%
DE